Literature DB >> 7594656

Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model.

C J Harrison1, W J Britt, N M Chapman, J Mullican, S Tracy.   

Abstract

This study evaluated the effects of subunit guinea pig (GP) cytomegalovirus (CMV) immunization on congenital infection. Two 25-micrograms doses of an abundant GPCMV glycoprotein, the gp60-90 complex, plus adjuvant to GPs before pregnancy produced virus-specific humoral (neutralizing and ELISA) and cellular (proliferative and delayed type hypersensitivity) responses. Viral challenge before midgestation resulted in shorter maternal viremia in immunized than in unimmunized dams (3 vs. 17 days). Litters of immunized dams had reduced organ involvement and rates of congenital infection (48% vs. 18%) and increased mean birth weights (74 vs. 99 g). Amplification of DNA extracted from pup blood or organs with primers from the gB gene of GPCMV revealed congenital infection in some pups without detectable CMV by classic culture techniques. These data suggest that induction of preconception immunity to CMV by vaccine could be useful in reducing both the incidence and severity of congenital CMV disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594656     DOI: 10.1093/infdis/172.5.1212

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.

Authors:  Fernando J Bravo; David I Bernstein; James R Beadle; Karl Y Hostetler; Rhonda D Cardin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  A study on the traditional Chinese medicine Jinyebaidu for prevention and treatment of intrauterine infection with guinea pigs cytomegalovirus.

Authors:  Suhua Chen; Jinwen Xiong; Wei Xing; Liangzhen Wen; Haizhi Liu; Xinrong Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

Review 4.  Immunobiology of human cytomegalovirus: from bench to bedside.

Authors:  Tania Crough; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

Review 5.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

Review 6.  Maternal vaccination: moving the science forward.

Authors:  Azure N Faucette; Benjamin L Unger; Bernard Gonik; Kang Chen
Journal:  Hum Reprod Update       Date:  2014-07-11       Impact factor: 15.610

7.  A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.

Authors:  K Yeon Choi; Matthew Root; Alistair McGregor
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

8.  Perinatal Listeria monocytogenes susceptibility despite preconceptual priming and maintenance of pathogen-specific CD8(+) T cells during pregnancy.

Authors:  Dayna R Clark; Vandana Chaturvedi; Jeremy M Kinder; Tony T Jiang; Lijun Xin; James M Ertelt; Sing Sing Way
Journal:  Cell Mol Immunol       Date:  2014-09-22       Impact factor: 11.530

9.  Guinea Pig Cytomegalovirus (GPCMV): A Model for the Study of the Prevention and Treatment of Maternal-Fetal Transmission.

Authors:  Mark R Schleiss; Michael A McVoy
Journal:  Future Virol       Date:  2010-03       Impact factor: 1.831

Review 10.  Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on.

Authors:  J Hassan; J Connell
Journal:  Clin Exp Immunol       Date:  2007-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.